Advance in Human Papillomavirus Major Capsid Protein L1-based Vaccines

Hua Chunting,Sun Siyuan,Cheng Hao,Han Rui
DOI: https://doi.org/10.3760/cma.j.issn.0254-5101.2019.010.011
2019-01-01
Abstract:L1 is the major capsid protein of human papillomavirus (HPV) encoded by late gene 1. Based on the fact that L1 can self-assemble into virus like particle (VLP) with good immunogenicity, it has aroused wide concern in studying the pathogenesis of and vaccines against HPV. Nevertheless, there are a few limitations of present L1-based HPV vaccines. For instance, low expression of the protein and the com-plexity of purification result in the relatively low yield of vaccines. Type-specific antibody induced by L1 also results in the unsatisfactory cross-protection rate. Furthermore, there is no reported therapeutic effect against HPV-related diseases because of its undefined role in virus eliminating. This review focused on the struc-ture, immunogenicity and role in immune response of L1 and the development of and latest progress in HPV vaccines.
What problem does this paper attempt to address?